Coherus Oncology, Inc.
CHRS
$1.22
$0.065.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 91.19% | -0.41% | 229.25% | -40.84% | -91.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.19% | -0.41% | 229.25% | -40.84% | -91.88% |
| Cost of Revenue | 36.35% | 87.67% | 84.36% | -59.96% | -91.66% |
| Gross Profit | 136.23% | -19.18% | 469.16% | 191.59% | -92.06% |
| SG&A Expenses | -18.83% | -5.36% | -12.17% | -27.31% | -38.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.69% | 11.65% | -10.86% | -42.11% | -49.11% |
| Operating Income | 9.87% | -14.79% | 20.55% | 43.94% | -59.34% |
| Income Before Tax | 6.47% | 18.21% | 30.33% | 36.35% | -18.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.47% | 18.21% | 30.33% | 36.35% | -20.08% |
| Earnings from Discontinued Operations | -75.61% | 717.15% | -105.37% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -230.49% | 2,404.52% | -154.99% | 36.35% | 72.88% |
| EBIT | 9.87% | -14.79% | 20.55% | 43.94% | -59.34% |
| EBITDA | 8.92% | -15.69% | 20.28% | 44.64% | -58.93% |
| EPS Basic | -227.65% | 2,380.18% | -153.52% | 38.52% | 77.00% |
| Normalized Basic EPS | 11.66% | -5.13% | 19.69% | -187.35% | -7.90% |
| EPS Diluted | -227.65% | 2,380.18% | -153.52% | 34.87% | 77.24% |
| Normalized Diluted EPS | 11.66% | -5.13% | 19.69% | -187.35% | -7.90% |
| Average Basic Shares Outstanding | 0.88% | 1.10% | 2.76% | 3.52% | 17.88% |
| Average Diluted Shares Outstanding | 0.88% | 1.10% | 2.76% | 3.52% | 17.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |